Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate Cancer

Lapi, Francesco; Azoulay, Laurent; Niazi, Mohammad; Yin, Hui; Benayoun, Serge; Suissa, Samy

doi:10.1001/jama.2013.8638

Cited by 99 publications

(81 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…injury (45,46). Deteriorated kidney tissue loses its capability to maintain its naturally functions resulting in disturbances in urine electrolytes (Table III).…”

Section: Cancer Patients Healthy Controls ---------------------------mentioning

confidence: 99%

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

et al. 2014

View full text Add to dashboard Cite

Abstract.Recently, interest in the identification of non-invasive markers for prostate carcinoma detectable in the urine of patients has increased. In this study, we monitored the abundance of potential non-invasive markers of prostate carcinoma such as amino acid sarcosine, involved in the metabolism of amino acids and methylation processes, ongoing during the progression of prostate carcinoma. In addition, other potential prostate tumor markers were studied. The most significant markers, prostate-specific antigen (PSA) and free PSA (fPSA), already used in clinical diagnosis, were analyzed using an immunoenzymometric assay. Whole amino acid profiles were also determined to evaluate the status of amino acids in patient urine samples and to elucidate the possibility of their utilization for prostate carcinoma diagnosis. To obtain the maximum amount of information, the biochemical parameters were determined using various spectrophotometric methods. All results were subjected to statistical processing for revealing different correlations between the studied parameters. We observed alterations in most of the analyzed substances. Based on the results obtained, we concluded that the specificity of prostate carcinoma diagnosis could be improved by determination of common urine metabolites, since we compiled a set of tests, including the analysis of sarcosine, proline, PSA and uric acid in the urine. These metabolites were not observed in the urine obtained from healthy subjects, while their levels were elevated in all patients suffering from prostate carcinoma.

show abstract

“…injury (45,46). Deteriorated kidney tissue loses its capability to maintain its naturally functions resulting in disturbances in urine electrolytes (Table III).…”

Section: Cancer Patients Healthy Controls ---------------------------mentioning

confidence: 99%

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In the United States, the use of ADT has increased sixfold in the last two decades [2], a trend that reflects the increasing use in patients with localized disease for whom the benefits are less clear [3,4]. This is particularly important in the context of the accumulating evidence suggesting that the hypogonadism induced by ADT may increase the risk of cardiovascular [5], cerebrovascular [6], and renal [7] adverse events, which some have attributed to accelerated atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…While ADT has been shown to prolong cancer-specific and overall survival in randomized trials, it has also been associated with significant toxicity, such as weight gain, decreased libido, fatigue, acute kidney injury, psychiatric illness, diabetes, and possibly an increased risk of cardiovascular events (8)(9)(10). Therefore, it is desirable to identify patients with high-risk disease who might be adequately treated with a shorter course of ADT than is typically recommended for this risk group.…”

Section: Introductionmentioning

confidence: 99%

Definition and Validation of “Favorable High-Risk Prostate Cancer”: Implications for Personalizing Treatment of Radiation-Managed Patients

Muralidhar

Chen

Reznor

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Patients with favorable high-risk prostate cancer have significantly better PCSM than other patients with high-risk disease and similar PCSM as those with unfavorable intermediate-risk disease, who are typically treated with shorter-course androgen deprivation therapy. This new classification system may allow for personalization of treatment within high-risk disease, such as consideration of shorter-course androgen deprivation therapy for favorable high-risk disease.

show abstract

Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate Cancer

Abstract: In a cohort of patients with newly diagnosed nonmetastatic prostate cancer, the use of ADT was significantly associated with an increased risk of AKI. These findings require replication in other well-designed studies as well as further investigation of their clinical importance.

Cited by 99 publications

References 35 publications

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism

Definition and Validation of “Favorable High-Risk Prostate Cancer”: Implications for Personalizing Treatment of Radiation-Managed Patients

Contact Info

Product

Resources

About